Lyophilisation Conference 2019

SMi Group3 - 4 June 2019, London, UK
SMi Group announces the return of the 7th Annual Lyophilisation Conference. Lyophilisation (or freeze drying) remains one of the most exciting and rapidly advancing technologies in the pharmaceutical industry to date. By 2020, the lyophilisation equipment market is projected to exceed 8% CAGR reaching approximately £4.4 billion.

Attend this conference along with key opinion leaders from all areas of pharmaceuticals and biologicals to explore formulation science, materials characterisation, novel and alternative technologies, mathematical modelling and regulatory updates.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2019

  • Sune Klint Andersen, Principal Spray Drying,Janssen Pharmaceuticals
  • Xiaodong Chen, Senior Research Investigator,Bristol-Myers Squibb

Key Speakers include

  • Paul Matejtschuk, Principal Scientist & Section Head, Standardisation Science, NIBSC
  • Davide Fissore, Associate Professor, Politecnico di Torino
  • Michael Dekner, Head Fill & Finish LCM support, Takeda
  • Richard Denk, Head Sales Containment, Skan AG
  • Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D
  • Daryl Williams, Professor of Particle Science and Director of Discovery space, Imperial College London
  • Kevin Ward, Director of R&D, Biopharma technology
  • Paul Barry, Development Scientist, Genzyme Ireland Ltd/Sanofi

2019 Highlights

  • Explore the recent advances in lyophilisation methods and technologies from Biopharma Technology
  • Discuss the novel methods that characterise complex pharmaceutical products to aid formulation design from NIBSC
  • Gain insight into the approaches to avoid cross contamination during lyophilisation from SKAN AG
  • Discover a new approach towards process design through the use of micro freeze dryers by Politecno di Torino
  • Examine the use of model-based approach to lyophilisation cycle design from Takeda

For further information and to register, please visit:
http://www.lyophilisation-europe.com/wpnwe

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...